FTC’s anti-consumer crusade on drug patent litigation
By: Daniel J. Popeo
Examiner Contributor, August 19, 2010
When it comes to Washington decision-making, the media, and in turn, the American public, devotes most if not all of its attention to Congress and the president. Such a focus regretfully distracts most Americans from the critical, and often economically destructive, work of federal regulatory agencies.
Anti-business activism at EPA, FDA, and the Department of Justice has received some scrutiny, but the lower-profile efforts of other powerful regulators remains far under the radar. Consider, for instance, the Federal Trade Commission’s (FTC) irrational crusade against settlements of patent litigation between branded pharmaceutical companies and generic drug makers
Click here to continue reading